N
LXEO icon

Nuveen’s Lexeo Therapeutics LXEO Stock Holding History

Nuveen’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Sell
182,975
-28,554
-13% -$202K ﹤0.01% 2568
2025
Q4 		$2.1M Buy
211,529
+178,427
+539% +$1.63M ﹤0.01% 2272
2025
Q3 		$220K Hold
33,102
– – ﹤0.01% 3135
2025
Q2 		$133K Sell
33,102
-2,948
-8% -$9.69K ﹤0.01% 3229
2025
Q1 		$125K Hold
36,050
– – ﹤0.01% 3195
2024
Q4 		$237K Hold
36,050
– – ﹤0.01% 3175
2024
Q3 		$326K Buy
36,050
+17,757
+97% +$212K ﹤0.01% 3127
2024
Q2 		$293K Buy
18,293
+4,815
+36% +$69.9K ﹤0.01% 3155
2024
Q1 		$211K Buy
+13,478
New +$211K ﹤0.01% 3171

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen's LXEO Position: Q1 2026 in Review

Nuveen reduced its Lexeo Therapeutics (LXEO) stake by 13% in Q1 2026, selling an estimated $202K and leaving 182,975 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2568.

Nuveen first reported a position in LXEO in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.1M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Nuveen held 182,975 shares of Lexeo Therapeutics worth $1.05M as of Q1 2026.
  • Nuveen sold 28,554 Lexeo Therapeutics shares in Q1 2026, an estimated $202K.
  • Lexeo Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2568 holding.
  • Nuveen first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Nuveen's Lexeo Therapeutics position peaked at $2.1M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.